ACCRETION PHARMA LIMITED Stock Price Today (NSE: ACCPL)
Fundamental Score
ACCRETION PHARMA LIMITED Share Price Live NSE/BSE & Institutional Fundamental Analysis
ACCRETION PHARMA LIMITED share price today is ₹64.05, up +0.00% on NSE/BSE as of 18 March 2026. ACCRETION PHARMA LIMITED (ACCPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹103.05 (Cr). The 52-week high for ACCPL share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 11.35x, ACCPL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 65.35% and a debt-to-equity ratio of 0.17.
ACCRETION PHARMA LIMITED Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
ACCRETION PHARMA LIMITED Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
ACCRETION PHARMA Share Price: A Financial Analysis for Growth
One key dynamic impacting the pharmaceutical industry is the increasing focus on generics and biosimilars to drive affordability and accessibility of medications globally. This analysis examines the financial standing of ACCRETION PHARMA LIMITED, focusing on its current share price and relative performance within the sector. Currently, the ACCRETION PHARMA share price stands at ₹66.55, exhibiting a Price-to-Earnings (PE) ratio of 11.35 and a Return on Capital Employed (ROCE) of 46.36%.
The PE ratio of 11.35 suggests that the market is valuing ACCRETION PHARMA LIMITED at a potentially reasonable level relative to its earnings. To contextualize this, let's consider its peers, including Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd. A key differentiator to investigate further is management quality. While quantitative metrics offer insight, qualitative aspects like
Mankind Pharma Ltd's strategic vision and execution capabilities (which are not explicitly captured in PE or ROCE) are crucial for sustained growth, representing a potential area where ACCRETION PHARMA LIMITED could focus on improvement.A particularly noteworthy figure is the company's ROCE of 46.36%. This exceptionally high ROCE indicates that ACCRETION PHARMA LIMITED is generating substantial returns on its invested capital. This impressive return significantly contributes to building the company's economic moat, implying a strong competitive advantage due to efficiency in capital allocation. Consistent high ROCE allows for reinvestment in research and development, expansion, and other growth initiatives, further solidifying its market position. A high ROCE can also indicate the presence of pricing power or operational efficiencies not easily replicated by competitors.
This financial analysis, part of an 80-parameter fundamental audit verified by Sweta Mishra, aims to provide an observational assessment of ACCRETION PHARMA LIMITED's current financial standing. Further detailed analysis would involve a deeper dive into the company's debt levels, cash flow generation, and specific product portfolio to obtain a more comprehensive understanding of its long-term growth potential.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ACCRETION PHARMA LIMITED Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ACCPL across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (65.35%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (46.36%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 11.35 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (93.09%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (135.67%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.60x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.52%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 1.16%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
ACCRETION PHARMA LIMITED Financial Statements
Comprehensive financial data for ACCRETION PHARMA LIMITED including income statement, balance sheet and cash flow
About ACCPL (ACCRETION PHARMA LIMITED)
ACCRETION PHARMA LIMITED (ACCPL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹103.05 (Cr). ACCRETION PHARMA LIMITED has delivered a Return on Equity (ROE) of 65.35% and a ROCE of 46.36%. The debt-to-equity ratio stands at 0.17, reflecting the company's capital structure. Investors tracking ACCPL share price can monitor key metrics including P/E ratio, promoter holding of 73.52%, and quarterly earnings growth.
Company Details
ACCPL Share Price: Frequently Asked Questions
What is the current share price of ACCRETION PHARMA LIMITED (ACCPL)?
As of 18 Mar 2026, 10:11 am IST, ACCRETION PHARMA LIMITED share price is ₹64.05. The ACCPL stock has a market capitalisation of ₹103.05 (Cr) on NSE/BSE.
Is ACCPL share price Overvalued or Undervalued?
ACCPL share price is currently trading at a P/E ratio of 11.35x, compared to the industry average of 31.77x. Based on this relative valuation, the ACCRETION PHARMA LIMITED stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ACCPL share price?
The 52-week high of ACCPL share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the ACCRETION PHARMA LIMITED share price?
Key factors influencing ACCPL share price include quarterly earnings growth (Sales Growth: 135.67%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is ACCRETION PHARMA LIMITED a good stock for long-term investment?
ACCRETION PHARMA LIMITED shows a 5-year Profit Growth of N/A% and an ROE of 65.35%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.17 before investing in ACCPL shares.
How does ACCRETION PHARMA LIMITED compare with its industry peers?
ACCRETION PHARMA LIMITED competes with major peers in the Pharmaceuticals. Investors should compare ACCPL share price P/E of 11.35x and ROE of 65.35% against the industry averages to determine competitive standing.
What is the P/E ratio of ACCPL and what does it mean?
ACCPL share price has a P/E ratio of 11.35x compared to the industry average of 31.77x. Investors pay ₹11 for every ₹1 of annual earnings.
How is ACCPL performing according to Bull Run's analysis?
ACCPL has a Bull Run fundamental score of 51.3/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ACCPL belong to?
ACCPL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting ACCRETION PHARMA LIMITED share price.
What is Return on Equity (ROE) and why is it important for ACCPL?
ACCPL has an ROE of 65.35%, which indicates excellent management efficiency. ROE measures how efficiently ACCRETION PHARMA LIMITED generates profits from shareholders capital.
How is ACCPL debt-to-equity ratio and what does it indicate?
ACCPL has a debt-to-equity ratio of 0.17, which indicates conservative financing with low financial risk.
What is ACCPL dividend yield and is it a good dividend stock?
ACCPL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in ACCRETION PHARMA LIMITED shares.
How has ACCPL share price grown over the past 5 years?
ACCPL has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in ACCPL and why does it matter?
Promoters hold 73.52% of ACCPL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in ACCRETION PHARMA LIMITED.
What is ACCPL market capitalisation category?
ACCPL has a market capitalisation of ₹103 crores, placing it in the Small-cap category.
How volatile is ACCPL stock?
ACCPL has a beta of N/A. A beta > 1 suggests the ACCRETION PHARMA LIMITED stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ACCPL operating profit margin trend?
ACCPL has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is ACCPL quarterly performance?
Recent quarterly performance shows ACCRETION PHARMA LIMITED YoY Sales Growth of 135.67% and YoY Profit Growth of 93.09%.
What is the institutional holding pattern in ACCPL?
ACCPL has FII holding of 1.16% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the ACCRETION PHARMA LIMITED stock.